Tower Research Capital (TRC)’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-5,075
| Closed | -$166K | – | 4423 |
|
|
2019
Q4 | $166K | Sell |
5,075
-8,839
| -64% | -$235K | 0.01% | 669 |
|
|
2019
Q3 | $263K | Sell |
13,914
-1,821
| -12% | -$40.9K | 0.02% | 869 |
|
|
2019
Q2 | $407K | Buy |
15,735
+13,275
| +540% | +$328K | 0.03% | 560 |
|
|
2019
Q1 | $72K | Sell |
2,460
-12,019
| -83% | -$341K | ﹤0.01% | 1586 |
|
|
2018
Q4 | $290K | Buy |
14,479
+7,293
| +101% | +$206K | 0.02% | 584 |
|
|
2018
Q3 | $318K | Sell |
7,186
-1,455
| -17% | -$58.7K | 0.02% | 732 |
|
|
2018
Q2 | $286K | Buy |
+8,641
| New | +$269K | 0.02% | 890 |
|
|
2018
Q1 | – | Sell |
-38,065
| Closed | -$1.28M | – | 4147 |
|
|
2017
Q4 | $1.28M | Buy |
+38,065
| New | +$1.3M | 0.17% | 136 |
|
|
2017
Q3 | – | Sell |
-4,112
| Closed | -$131K | – | 4320 |
|
|
2017
Q2 | $131K | Buy |
4,112
+1,686
| +69% | +$47.3K | 0.01% | 416 |
|
|
2017
Q1 | $67K | Sell |
2,426
-6,302
| -72% | -$166K | 0.01% | 617 |
|
|
2016
Q4 | $184K | Sell |
8,728
-4,905
| -36% | -$116K | 0.02% | 666 |
|
|
2016
Q3 | $396K | Sell |
13,633
-19,208
| -58% | -$547K | 0.04% | 220 |
|
|
2016
Q2 | $697K | Buy |
32,841
+31,884
| +3,332% | +$808K | 0.07% | 203 |
|
|
2016
Q1 | $23K | Sell |
957
-1,940
| -67% | -$53.5K | ﹤0.01% | 1258 |
|
|
2015
Q4 | $167K | Buy |
+2,897
| New | +$153K | 0.03% | 214 |
|
|
2015
Q3 | – | Sell |
-40
| Closed | -$4K | – | 5124 |
|
|
2015
Q2 | $4K | Buy |
+40
| New | +$3.7K | ﹤0.01% | 3443 |
|
Other funds holding UBIO
Tower Research Capital (TRC)'s UBIO Position: Q1 2020 in Review
Tower Research Capital (TRC) sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q1 2020, closing a stake of 5,075 shares — an estimated $166K sold.
Tower Research Capital (TRC) first reported a position in UBIO in Q2 2015 and held it in 16 quarters. The position peaked at $1.28M in Q4 2017. 1 fund tracked by Wall St. Rank holds UBIO as of Q1 2020.
- Tower Research Capital (TRC) reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
- Tower Research Capital (TRC) sold 5,075 Proshares UltraPro NASDAQ Biotechnology shares in Q1 2020, an estimated $166K.
- Tower Research Capital (TRC) first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q2 2015 and held it in 16 quarters.
- Tower Research Capital (TRC)'s Proshares UltraPro NASDAQ Biotechnology position peaked at $1.28M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q1 2020.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2020, filed 15 May 2020.